ANN ARBOR, Mich., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced that final 12-month results from the RESTORE-CLI Phase 2b clinical trial for ixmyelocel-T will be presented by William Marston, MD, chief, Division of Vascular Surgery at the UNC Department of Surgery, on Monday, November 14, 2011 at the American Heart Association Scientific Sessions 2011 in Orlando, FL. Dr. Marston is the national co-principal investigator of the RESTORE-CLI clinical trial. The oral presentation will begin at 11:15 am. The presentation will also be available on the Aastrom web site that same day.
